Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - Blood, 2003 - ashpublications.org
Abstract In the European Organization for Research and Treatment of Cancer Leukemia
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
[HTML][HTML] Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete …
S Kurosawa, T Yamaguchi, N Uchida… - Biology of Blood and …, 2011 - Elsevier
The benefits of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with
acute myelogenous leukemia (AML) in first complete remission (CR1) have mostly been …
acute myelogenous leukemia (AML) in first complete remission (CR1) have mostly been …
Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk …
RF Schlenk, K Döhner, S Mack, M Stoppel… - Journal of Clinical …, 2010 - ascopubs.org
Purpose To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT)
from matched related donors (MRDs) and matched unrelated donors (MUDs) on outcome in …
from matched related donors (MRDs) and matched unrelated donors (MUDs) on outcome in …
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete …
The preferred post-remission therapy for older patients with acute myeloid leukemia (AML)
in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study …
in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study …
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
The probability that adult patients with de novo acute myeloid leukemia (AML) receiving
intensive chemotherapy in the absence of allogeneic hematopoietic stem cell …
intensive chemotherapy in the absence of allogeneic hematopoietic stem cell …
[HTML][HTML] Outcome of allogeneic hematopoietic stem cell transplantation in patients age> 69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia …
Reduced-intensity conditioning (RIC) allows for the use of allogeneic hematopoietic stem
cell transplantation (HSCT) in older patients with acute myelogenous leukemia (AML). We …
cell transplantation (HSCT) in older patients with acute myelogenous leukemia (AML). We …
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years
JJ Cornelissen, J Versluis, JR Passweg… - Leukemia, 2015 - nature.com
The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia
(AML) in first complete remission (CR1) is a subject of continued debate, especially in …
(AML) in first complete remission (CR1) is a subject of continued debate, especially in …
[HTML][HTML] Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow …
D Weisdorf, M Eapen, A Ruggeri, MJ Zhang… - Biology of Blood and …, 2014 - Elsevier
We studied patients with acute myeloid leukemia (AML) over age 50 and in first complete
remission (CR1) after adult unrelated donor (URD)(n= 441, 8/8 HLA matched; n= 94, 7/8 …
remission (CR1) after adult unrelated donor (URD)(n= 441, 8/8 HLA matched; n= 94, 7/8 …
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis
BACKGROUND The efficacy of allogeneic hematopoietic stem cell transplantation (allo‐
HSCT) from a human leukocyte antigen‐identical sibling donor remains controversial for …
HSCT) from a human leukocyte antigen‐identical sibling donor remains controversial for …
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …
JJ Cornelissen, WLJ Van Putten, LF Verdonck… - Blood, 2007 - ashpublications.org
Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for
Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of …
Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of …